Maynard Um
-
-
-
-
-
-
-
William Blair on ARS Pharmaceuticals Inc (SPRY): FDA label update 'viewed positively'
-
-
-
-
-
-
-
ARS Pharmaceuticals, Inc. (SPRY) Misses Q3 EPS by 6c
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY)
-
-
-
-
-
-
-
ARS Pharmaceuticals Inc (SPRY) PT Raised to $32 at Raymond James
-
-
-
-
-
-
-
ARS Pharmaceuticals (SPRY) Announces U.S. Availability of neffy, the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
-
-
-
-
-
-
407,831 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

